A clinician’s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution?

References

• CammAJKirchhofPLipGYGuidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)Eur Heart J2010312369242920802247
   PubMed Web of Science ®Google Scholar
• ColillaSCrowASimonTProjected estimates of prevalence and annual growth rate of atrial fibrillation in the United States from a dynamic age-period progression modelCirc Cardiovasc Qual Outcomes20125A2056
   Google Scholar
• WolfPAAbbottRDKannelWBAtrial fibrillation as an independent risk factor for stroke: the Framingham StudyStroke1991229839881866765
   PubMed Web of Science ®Google Scholar
• [No authors listed]Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trialsArch Intern Med1994154144914578018000
   PubMed Web of Science ®Google Scholar
• Bristol-Myers SquibbCoumadin^® (prescribing information) Available from: http://packageinserts.bms.com/pi/pi_coumadin.pdfAccessed October 11, 2013
   Google Scholar
• Boehringer IngelheimPradaxa^® (dabigatran etexilate) capsules (prescribing information) Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdfAccessed September 18, 2013
   Google Scholar
• Bristol-Myers SquibbEliquis^® (apixaban tablets, prescribing information) Available from: http://packageinserts.bms.com/pi/pi_eliquis.pdfAccessed March 20, 2014
   Google Scholar
• Janssen PharmaceuticalsXarelto^® (rivaroxaban tablets, prescribing information) Available from: http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100Accessed October 8, 2013
   Google Scholar
• MendellJZahirHMatsushimaNDrug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitorAm J Cardiovasc Drugs20131333134223784266
   PubMed Web of Science ®Google Scholar
• OgataKMendell-HararyJTachibanaMClinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteersJ Clin Pharmacol20105074375320081065
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med20093611139115119717844
   PubMed Web of Science ®Google Scholar
• ConnollySJEikelboomJJoynerCApixaban in patients with atrial fibrillationN Engl J Med201136480681721309657
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med201136598199221870978
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med201136588389121830957
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSNewly identified events in the RE-LY trialN Engl J Med20103631875187621047252
   PubMed Web of Science ®Google Scholar
• GiuglianoRPRuffCTBraunwaldEEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med20133692093210424251359
   PubMed Web of Science ®Google Scholar
• AlexanderJHLevyELawrenceJDocumentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE trialAm Heart J201316655956524016507
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationCenter for Drug Evaluation and ResearchApplication number 202155Orig1s000. Summary review Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000SumR.pdfAccessed June 3, 2013
   Google Scholar
• Bristol-Myers Squibb, Pfizer EEIGEliquis^® (apixaban tablets) Summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdfAccessed June 2, 2014
   Google Scholar
• UchinoKHernandezAVDabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trialsArch Intern Med201217239740222231617
   PubMed Web of Science ®Google Scholar
• HohnloserSHOldgrenJYangSMyocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trialCirculation201212566967622215856
   PubMed Web of Science ®Google Scholar
• HeidbuchelHVerhammePAlingsMEuropean Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillationEuropace20131562565123625942
   PubMed Web of Science ®Google Scholar
• HarperPYoungLMerrimanEBleeding risk with dabigatran in the frail elderlyN Engl J Med201236686486622375994
   PubMed Web of Science ®Google Scholar
• LegrandMMateoJAribaudAThe use of dabigatran in elderly patientsArch Intern Med20111711285128621788545
   PubMed Web of Science ®Google Scholar
• WoodSDeaths prompt dabigatran safety advisory in Japan Available from: http://www.medscape.com/viewarticle/748143Accessed April 24, 2014
   Google Scholar
• EikelboomJWWallentinLConnollySJRisk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trialCirculation20111232363237221576658
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyQuestions and answers on the review of bleeding risk with Pradaxa (dabigatran etexilate) Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/05/WC500127768.pdfAccessed November 1, 2012
   Google Scholar
• SouthworthMRReichmanMEUngerEFDabigatran and postmarketing reports of bleedingN Engl J Med20133681272127423484796
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationDrug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin5132014 Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM397606.pdfAccessed June 4, 2014
   Google Scholar
• LarsenTBRasmussenLHSkjothFEfficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort studyJ Am Coll Cardiol2013612264227323562920
   PubMed Web of Science ®Google Scholar
• HoJCChangAMYanBPDabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong KongClin Cardiol201235E40E4523108916
   PubMed Web of Science ®Google Scholar
• GoodmanSGWojdylaDMWhiteHDPredictors of major bleeding risk: insights from the rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Circulation2011124A16903
   Google Scholar
• PicciniJPGargJPatelMRManagement of major bleeding events in patients treated with rivaroxaban vs warfarin: results from the ROCKET AF trialEur Heart J2014351873188024658769
   PubMed Web of Science ®Google Scholar
• HohnloserSHHijaziZThomasLEfficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trialEur Heart J2012332821283022933567
   PubMed Web of Science ®Google Scholar
• HylekEMHeldCAlexanderJHMajor bleeding in patients with atrial fibrillation receiving apixaban or warfarin in the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomesJ Am Coll Cardiol2014632141214724657685
   PubMed Web of Science ®Google Scholar
• BarrettYCWangZFrostCShenkerAClinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assayThromb Haemost20101041263127120978714
   PubMed Web of Science ®Google Scholar
• GarciaDBarrettYCRamacciottiEWeitzJILaboratory assessment of the anticoagulant effects of the next generation of oral anticoagulantsJ Thromb Haemost20131124525223216682
   PubMed Web of Science ®Google Scholar
• LiesenfeldKHSchaferHGTroconizIFEffects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysisBr J Clin Pharmacol20066252753717061960
   PubMed Web of Science ®Google Scholar
• SamamaMMMartinoliJLLe FlemLAssessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitorThromb Haemost201010381582520135059
   PubMed Web of Science ®Google Scholar
• StangierJFeuringMUsing the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatranBlood Coagul Fibrinolysis20122313814322227958
   PubMed Web of Science ®Google Scholar
• van RynJRuehlDPriepkeHReversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrateHaematologica200893148
   Web of Science ®Google Scholar
• WongPCCrainEJXinBApixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesJ Thromb Haemost2008682082918315548
   PubMed Web of Science ®Google Scholar
• HawesEMDealAMFunk-AdcockDPerformance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levelsJ Thromb Haemost2013111493150223718677
   PubMed Web of Science ®Google Scholar
• BeckerRCYangHBarrettYChromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban – an oral, direct and selective factor Xa inhibitorJ Thromb Thrombolysis20113218318721516308
   PubMed Web of Science ®Google Scholar
• SamamaMMAmiralJGuinetCAn optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasmaThromb Haemost20101041078107920806114
   PubMed Web of Science ®Google Scholar
• MiyaresMADavisKNewer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patientAm J Health Syst Pharm2012691473148422899742
   PubMed Web of Science ®Google Scholar
• WolztMWeltermannANieszpaur-LosMStudies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in manThromb Haemost1995734394437667826
   PubMed Web of Science ®Google Scholar
• ZhouWSchwartingSIllanesSHemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatranStroke2011423594359921998060
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Advisory Committee Briefing BookRivaroxaban for the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM138385.pdfAccessed February 19, 2012
   Google Scholar
• WangXMondalSWangJEffect of activated charcoal on apixaban pharmacokinetics in healthy subjectsAm J Cardiovasc Drugs20141414715424277644
   PubMed Web of Science ®Google Scholar
• EerenbergESKamphuisenPWSijpkensMKReversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjectsCirculation20111241573157921900088
   PubMed Web of Science ®Google Scholar
• MarluRHodajEParisAEffect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteersThromb Haemost201210821722422627883
   PubMed Web of Science ®Google Scholar
• EscolarGArellano-RodrigoEReverterJCReversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human bloodCirculation2012126520521
   Google Scholar
• CrowtherMKittMLorenzTA phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitorsJ Thromb Haemost201311Suppl 230
   Google Scholar
• CrowtherMMathurVKittMA phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitorsAbstract presented at the 55th Annual Meeting of the American Society of HematologyDecember 7–10, 2013New Orleans, LA, USA
   Google Scholar
• GrangerCAlexanderJHHannaMEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trialEur Heart J201233Suppl685686
   Google Scholar
• LakkireddyDReddyYMDi BiaseLFeasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registryJ Am Coll Cardiol2012591168167422305113
   PubMed Web of Science ®Google Scholar
• PatelMRHellkampASLokhnyginaYOutcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)J Am Coll Cardiol20136165165823391196
   PubMed Web of Science ®Google Scholar
• PicciniJPStevensSRLokhnyginaYOutcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trialJ Am Coll Cardiol2013611998200623500298
   PubMed Web of Science ®Google Scholar
• DouketisJDSpyropoulosACSpencerFAPerioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141e326Se350S22315266
   PubMed Web of Science ®Google Scholar
• LarsenTBRasmussenLHGorst-RasmussenAMyocardial ischemic events in “real world” patients with atrial fibrillation treated with dabigatran or warfarinAm J Med2014127329336.e424361757
   PubMed Web of Science ®Google Scholar
• JanuaryCTWannLSAlpertJS2014AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm SocietyJ Am Coll Cardiol2014pii:S0735–1097(14)01740–01749
   Google Scholar
• EitelCKochJSommerPNovel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillationEuropace2013151587159323703362
   PubMed Web of Science ®Google Scholar
• ProvidenciaRMarijonEAlbenqueJPRivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillationEuropace2014161137114424550347
   PubMed Web of Science ®Google Scholar
• SardarPNairoozRChatterjeeSMeta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablationAm J Cardiol20141131173117724513472
   PubMed Web of Science ®Google Scholar
• StepanyanGBadhwarNLeeRJSafety of new oral anticoagulants for patients undergoing atrial fibrillation ablationJ Interv Card Electrophysiol20144333824643666
   PubMedGoogle Scholar
• WinkleRAMeadRHEngelGThe use of dabigatran immediately after atrial fibrillation ablationJ Cardiovasc Electrophysiol20122326426821955008
   PubMed Web of Science ®Google Scholar
• HealeyJSEikelboomJDouketisJPeriprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trialCirculation201212634334822700854
   PubMed Web of Science ®Google Scholar
• LopesRDGarciaDAWojdylaDMUse of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLEEur Heart J201334Suppl9899
   Google Scholar
• EzekowitzMDConnollySParekhARationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranAm Heart J200915780581019376304
   PubMed Web of Science ®Google Scholar
• NagarakantiREzekowitzMDOldgrenJDabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversionCirculation201112313113621200007
   PubMed Web of Science ®Google Scholar
• FlakerGLopesRDAl-KhatibSMApixaban and warfarin are associated with a low risk of stroke following cardioversion for atrial fibrillation: results from the ARISTOTLE trialEur Heart J201233686
   Web of Science ®Google Scholar
• WallentinLYusufSEzekowitzMDEfficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trialLancet201037697598320801496
   PubMed Web of Science ®Google Scholar
• WallentinLLopesRDHannaMEfficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillationCirculation20131272166217623640971
   PubMed Web of Science ®Google Scholar
• CammAJLipGYDe CaterinaR2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm AssociationEur Heart J2012332719274722922413
   PubMed Web of Science ®Google Scholar
• SchulmanSShorttBRobinsonMEikelboomJWAdherence to anticoagulant treatment with dabigatran in a real-world settingJ Thromb Haemost2013111295129923855420
   PubMed Web of Science ®Google Scholar
• SorensenRGislasonGTorp-PedersenCDabigatran use in Danish atrial fibrillation patients in 2011: a nationwide studyBMJ Open20133
   Web of Science ®Google Scholar
• FoxKAPicciniJPWojdylaDPrevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentEur Heart J2011322387239421873708
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCSubcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and HaemostasisDefinition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patientsJ Thromb Haemost2005369269415842354
   PubMed Web of Science ®Google Scholar
• GuQDillionCFBurtVLNCHC Data brief: prescription drug use continues to increase: US prescription drug data for 2007–2008 Available from: http://www.cdc.gov/nchs/data/databriefs/db42.htmAccessed June 6, 2013
   Google Scholar
• FreemanJVZhuRPOwensDKCost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillationAnn Intern Med201115411121041570
   PubMed Web of Science ®Google Scholar
• KamelHEastonJDJohnstonSCKimASCost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillationNeurology2012791428143422993279
   PubMed Web of Science ®Google Scholar
• LeeSAngladeMWMengJCost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarinCirc Cardiovasc Qual Outcomes2012547247922740012
   PubMed Web of Science ®Google Scholar
• LeeSAngladeMWPhamDCost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillationAm J Cardiol201211084585122651881
   PubMed Web of Science ®Google Scholar
• DeitelzweigSAminAJingYMedical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE trialsJ Med Econ20121577678522449118
   PubMedGoogle Scholar
• LipGYHKongnakornTPhatakHCost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillationClin Ther20143619221024508420
   PubMed Web of Science ®Google Scholar
• American College of CardiologyRegistry data shows early patterns for new atrial fibrillation treatments Available from: http://www.cardiosource.org/News-Media/Media-Center/News-Releases/2012/08/PINN-AF.aspxAccessed October 15, 2012
   Google Scholar